Friday, March 22, 2024 12:59:09 PM
Financial Times
Neil Woodford
The longtime links between Neil Woodford and a City broking minnow
Cenkos Securities has often managed to secure backing from the former star stock picker
The relationship between Neil Woodford and Cenkos Securities has bemused rivals.
Cat Rutter Pooley, City Correspondent JUNE 27 2019
Print this page
For almost 15 years, a minnow of London’s broking world has had an impressive ability to secure investment from Neil Woodford, the once star stock picker whose flagship fund is now grappling with a flood of investor redemptions.
The relationship between Mr Woodford and Cenkos Securities, which has specialised in bringing some of the UK’s smallest public companies to market since it was founded in 2004, has bemused rivals and fed City chatter.
Half of Cenkos’s top-20 equity fundraisings by value since the start of 2014 — when Mr Woodford left Invesco and struck out on his own — were in stocks where Woodford Investment Management disclosed an interest, according to Bloomberg data.
Among the deals the two did together were the refinancing of AA and the £1.2bn reverse takeover of used car dealership BCA Marketplace, which was bought by a private equity group this week. Cenkos also brought to market less well known companies, including Woodford-backed biotechnology groups Verseon and Abzena.
Recommended
Neil Woodford
Woodford Patient Capital unveils plans to sell assets to reduce debt
“It was for a while almost a given that any deal from Cenkos, whether it fitted with Woodford’s fund or not, would come into consideration,” said one investment adviser.
In the view of a rival broker: “[Woodford] consistently took issues from [Cenkos] that he wouldn’t take from other people.”
Cenkos said that “contrary to speculation there is no special relationship with Neil Woodford” and that it has “a standard arms-length relationship with its fund management clients, Mr Woodford’s funds being just one of many.”
Recent NWBO News
- How Advanced Drug Delivery Could Improve Existing Cancer Treatments • GlobeNewswire Inc. • 06/01/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
